Allosteric Modulators of 5-HT2CR Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional specific allosteric modulators of the 5-HT2C receptor (5-HT2CR) to address therapeutic challenges in diseases such as addiction, anxiety, depression, obesity, and schizophrenia, as existing modulators lack selectivity and understanding of structure-activity relationships.
Innovation Solution
Development of piperidine-, piperazine-, and benzazepine-based small molecule allosteric modulators that bind to sites other than the primary ligand binding site on the 5-HT2CR, optimizing their structure to achieve high selectivity and potency, and synthesizing compounds like CYD-1-78-2, CYD-1-79, and CYD-1-84 to demonstrate functional activity and therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional screening methods are used to detect standard orthosteric agonists and antagonists, then the screening process is optimized and well-understood, but the discovery of allosteric ligands is limited and selective modulators of 5-HT2CR are scarce
Solution Approach 1:
The patent applies preliminary action by establishing structure-activity relationship (SAR) studies before full-scale drug development. The inventors systematically explored the structural requirements for allosteric modulation at the 5-HT2CR, identifying key pharmacophore elements and binding site characteristics that enable selective allosteric modulator activity, thereby preparing foundational knowledge for future therapeutic development
Solution Approach 2:
The patent utilizes parameter changes by modifying molecular structures of potential allosteric modulators to optimize their binding affinity and modulatory activity at the 5-HT2CR. The inventors adjusted various structural parameters including substituent types, molecular size, and spatial configuration to achieve high selectivity and potency, transforming lead compounds into optimized therapeutic candidates
2Reliability
If selective allosteric modulators of 5-HT2CR are developed, then therapeutic selectivity and potency are improved, but the complexity of structure optimization and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core scaffold region that provides binding affinity and a substituent region that fine-tunes modulatory activity and selectivity. This modular approach allows independent optimization of each segment, simplifying the overall structure-activity relationship analysis and synthesis strategy while achieving high therapeutic reliability
Solution Approach 2:
The patent implements local quality by introducing specific functional groups and substituents at particular positions within the molecular structure to achieve selective allosteric modulation. The inventors strategically placed pharmacophore elements at critical binding site regions, creating local structural features that confer high selectivity for 5-HT2CR over other serotonin receptors, thereby improving therapeutic reliability without requiring complete structural complexity
3Adaptability or versatility
If additional allosteric modulators are synthesized and characterized, then therapeutic options for various diseases are expanded, but the time and resources required for identification and synthesis increase
Solution Approach 1:
The patent applies universality by designing a versatile SAR framework that can generate multiple allosteric modulators with different activity profiles (positive, negative, and neutral) from a unified structural approach. The established binding site characteristics and pharmacophore elements can be applied across different disease indications, allowing the same structural principles to yield therapeutic candidates for addiction, anxiety, depression, obesity, and schizophrenia, thereby expanding therapeutic options without proportionally increasing development time
Data Source
AI summary
The disclosure is directed to compounds identified as allosteric modulators of 5-HT 2CR, as well as pharmaceutical compositions and methods using the same. Certain embodiments also include methods of identifying and methods of synthesizing the compounds. Optimization and development of allosteric 5-HT 2CR modulators that bind sites other than the primary ligand binding site generate novel, highly selective, and potent ligands of 5-HT2CR. Such molecules can be used as small molecule probes for the nervous system and as effective therapeutics for a variety of diseases.